Intercept (ICPT) 'Breaking Away from the Competition', Nomura Says

Intercept Pharmaceuticals (ICPT) Outperform, $493 PT Reiterated at Wedbush

Wedbush analyst Liana Moussatos reiterated an Outperform rating and $493 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) saying the recent data presentations and KOL comments straighten OCA's clinical profile.

"OCA improvement in liver histology across all stages of fibrosis and in high-risk NASH patients reduces clinical risk for... More

Intercept Pharmaceuticals (ICPT) PT Bumped to $265 at Leerink Partners; Remains on Sidelines

Leerink Partners analyst Joseph Schwartz raised his price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $265.00 (from $205.00) but maintained a Market Perform rating on the stock.

Schwartz commented, "We update our estimates to reflect the industry-academia dialogue at AASLD-IC around ICPT's: (a) better-than-expected PBC... More

Intercept (ICPT) Bullish Stance Reiterated at Needham & Company Amid AASLD Industry Colloquium Review

Needham & Company analyst Alan Carr reiterated a Buy rating and $500 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after the AASLD Industry Colloquium Review.

Carr commenetd, "Intercept presented additional OCA NASH Phase 2 trial data and hosted an analyst/investor mtg at the AASLD... More

Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at Wedbush

Wedbush analyst Liana Moussatos reiterated an Outperform rating and $493 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after new subgroup analyses from the Phase 2b FLINT trial of OCA in patients with NASH at the American Association for the Study of Liver Disease (AASLD) and... More

Intercept (ICPT) FLINT Analysis Shows LDL Elevations Can Be Managed, Baird Says

Baird analyst Brian Skorney reiterated an Outperform rating and $344 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after Phase 2 FLINT analysis shows LDL elevation can be managed.

Skorney commented, "Following data presented today at a scientific conference, we believe investors should have increased... More

Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at BMO Capital Amid Data

BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $515 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following a subgroup analysis from the FLINT trial in NASH.

commented, "We are reiterating our Outperform rating on shares of ICPT following review of LDL... More

RBC Capital Comments on Intercept (ICPT) Phase 2b Flint Data

RBC Capital maintained an rating on Intercept Pharmaceuticals (NASDAQ: ICPT) with a price target of $490. Comments follow an update on new subgroup analyses from the Phase 2b FLINT trial of obeticholic acid (OCA) in patients with NASH.

Analyst Michael J. Yee said analysis shows robust stat-sig benefit on multiple endpoints within the high-risk subset as well as favorable statin benefit. More... More

Intercept Pharma (ICPT) Updates on Phase 2b FLINT Ahead of AASLD Presentation

Intercept Pharma (Nasdaq: ICPT) announced new subgroup analyses from the Phase 2b FLINT trial of obeticholic acid (OCA) in patients with nonalcoholic steatohepatitis (NASH). Intercept is presenting the data in two posters during today's poster session at the American Association for the Study of Liver Disease (AASLD) and Industry Colloquium: Novel Targets and Therapies in Liver Disease.

Obeticholic acid (OCA) is a first-in-class farnesoid X receptor (FXR) agonist being developed for primary biliary cirrhosis (PBC), NASH and other chronic liver indications. Intercept has initiated a rolling New Drug Application with... More